Specifically, there were 7 cases (2.32%) of ZNF384 rearrangement, among which 85.7% (6/7) were correlated with the pre-B-cell acute lymphoblastic leukemia (pre-B-ALL) immunophenotype; 5 cases (1.66%) of DUX4 rearrangement, for which no clear association with immunophenotype was found; and 3 cases (0.99%) of NUP214/ABL1 fusion, and subsequent clinical observations revealed that this subtype exhibited sensitivity to imatinib. This evidence concerns the gene DUX4 and B-cell acute lymphoblastic leukemia.